Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) for the first-line treatment of patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OSCC). Update June 2022

Rothschedl, E. and Wolf, S. (2022): Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) for the first-line treatment of patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OSCC). Update June 2022. Oncology Fact Sheet Nr. 82.

[thumbnail of Oncology Fact Sheet Nr.82_Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
139kB

Item Type:	Oncology Fact Sheet
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WI Digestive system > WI 250 Oesophagus
Language:	English
Series Name:	Oncology Fact Sheet Nr. 82
Deposited on:	28 Mar 2022 12:39
Last Modified:	11 Jul 2022 13:37

Repository Staff Only: item control page